V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10465806 | 10042270 | 1.71 | 63.2 | 03 | 2019-08-07 | 2019-08-07 | CTD | 02 | N | ATEZOLIZUMAB | 100242858 |
| 10465829 | 10042271 | 0 | null | Palliative (P) | 2017-02-15 | 2017-02-20 | AVELUMAB + AXITINIB | 02 | N | ANAGRELIDE | 101244690 |
| 10465839 | 10042272 | 1.6 | 74.4 | 03 | 2019-11-14 | 2019-12-07 | VEPEMB | 02 | null | CTD | 100496246 |
| 10465901 | 10042273 | 1.63 | 78.5 | Curative (C) | 2017-12-17 | 2018-01-12 | Ipilimumab | 02 | null | CVD | 100757464 |
| 10465984 | 10042274 | 1.58 | null | Curative (C) | 2019-03-23 | 2019-03-23 | Bexarotene | 02 | N | RIBOCICLIB | 100719306 |
| 10465999 | 10042275 | 1.65 | null | Curative (C) | null | 2020-01-23 | MPT | null | null | CARBOPLATIN + LIPOSOMAL DOXORUBICIN | 101546072 |
| 10466000 | 10042276 | 1.7 | 92 | Palliative (P) | 2019-05-14 | 2019-05-29 | Bortezomib + Panobinostat | 02 | N | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 101755483 |
| 10466066 | 10042277 | null | null | Adjuvant (A) | 2017-10-09 | 2017-10-31 | Cisplatin + Pemetrexed | 02 | N | CYTARABINE + ETOPOSIDE | 101073213 |
| 10466125 | 10042278 | 1.66 | 95 | 03 | 2018-11-24 | 2018-11-24 | CAPECITABINE + TEMOZOLOMIDE | 02 | N | CARBOPLATIN + CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 100035444 |
| 10466178 | 10042279 | 1.59 | null | 03 | 2018-03-02 | 2018-03-02 | Rituximab + Venetoclax | 02 | N | CARBOPLATIN + DOCETAXEL | 101557693 |
| 10466196 | 10042280 | 1.72 | 53.5 | null | 2016-07-01 | 2016-07-10 | FEC | 01 | N | APALUTAMIDE | 100317724 |
| 10466233 | 10042281 | 1.54 | 67.4 | Palliative (P) | 2020-01-16 | 2020-01-28 | VEDex | 02 | N | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | 101386523 |
| 10466432 | 10042283 | 1.67 | 54.8 | Disease modification (D) | null | 2016-09-21 | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB | N | N | CHOP | 101256506 |
| 10466480 | 10042285 | 1.64 | 79 | 03 | 2017-03-28 | 2017-04-28 | Sorafenib | 02 | null | AML17 TRIAL | 101199601 |
| 10466499 | 10042286 | null | null | Palliative (P) | 2019-01-22 | 2019-01-22 | CISPLATIN + GEMCITABINE + RITUXIMAB | 02 | null | MYELOMA XI TRIAL | 100948302 |
| 10466572 | 10042287 | 1.75 | 63.7 | Palliative (P) | 2019-06-17 | 2019-07-01 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | AFATINIB | 100207502 |
| 10466573 | 10042288 | 1.81 | 62.3 | 03 | 2017-12-12 | 2017-12-17 | null | 01 | N | PRIMUS 002 TRIAL | 100469967 |
| 10466578 | 10042289 | 1.73 | 59.7 | 03 | 2018-02-18 | 2018-02-19 | null | null | N | CISPLATIN + ETOPOSIDE | 100674194 |
| 10466639 | 10042291 | 1.62 | 67.5 | 03 | 2022-02-20 | 2022-02-22 | Cetuximab + FOLFIRI cycle1 | null | null | CHLVPP | 101407848 |
| 10466700 | 10042292 | 0 | 0 | null | 2018-02-23 | 2018-07-16 | null | 02 | null | CABAZITAXEL | 101345294 |
| 10466714 | 10042293 | 1.75 | 63.9 | Curative (C) | 2017-10-25 | 2017-11-04 | Alectinib | 02 | N | DOXORUBICIN EMBOLISATION | 100093732 |
| 10466767 | 10042294 | null | 77.9 | Palliative (P) | 2004-08-30 | 2021-03-28 | CAPECITABINE + MITOMYCIN + RT | 02 | N | NILOTINIB | 101582196 |
| 10466858 | 10042295 | 1.78 | 63.3 | null | 2015-12-11 | 2015-12-12 | Cisplatin + Pemetrexed | 02 | N | CHOP | 101035522 |
| 10466860 | 10042296 | null | null | Palliative (P) | null | 2017-05-19 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | N | null | MELPHALAN + THALIDOMIDE | 100865503 |
| 10466955 | 10042299 | 1.6 | 99.8 | Curative (C) | 2019-05-11 | 2019-05-12 | ACELARATE Trial | 02 | N | BORTEZOMIB + MELPHALAN | 100957732 |
| 10466999 | 10042301 | 1.6 | 53.4 | Palliative (P) | null | 2017-10-05 | MATRIX (lymphoma) | 01 | N | BRENTUXIMAB VEDOTIN + CYCLOPHOSPHAMIDE + DOXORUBICIN | 101180229 |
| 10467140 | 10042305 | 1.76 | 84 | 03 | 2017-09-02 | 2017-09-14 | Fludarabine + Melphalan RIC Allo | 02 | null | CHOP | 100096909 |
| 10467170 | 10042306 | null | 0 | Disease modification (D) | null | 2022-03-08 | Nilotinib | 01 | null | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101001705 |
| 10467175 | 10042307 | 1.46 | 77 | Curative (C) | 2019-01-16 | 2019-01-16 | Paclitaxel+Trastuzumab wkly Maint | 02 | N | EVEROLIMUS | 101641637 |
| 10467201 | 10042308 | 1.76 | null | Curative (C) | 2018-01-20 | 2018-01-26 | AZACITIDINE + VENETOCLAX | 02 | N | SORAFENIB | 101341222 |
| 10467214 | 10042309 | null | null | null | 2018-05-27 | 2018-05-27 | AZACITIDINE + VENETOCLAX | Y | N | IDELALISIB + RITUXIMAB | 101200479 |
| 10467290 | 10042310 | 1.56 | 85.95 | Curative (C) | 2016-05-05 | 2016-05-21 | AVELUMAB + AXITINIB | 02 | null | AML – CYTARABINE | 101496437 |
| 10467370 | 10042312 | 1.67 | 91.9 | Palliative (P) | 2019-08-21 | 2019-08-21 | INTERFERON | 02 | N | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 101407421 |
| 10467468 | 10042314 | 1.69 | 92 | Neo-adjuvant (N) | 2022-02-05 | 2022-02-14 | ECX | N | null | FLUOROURACIL + MITOMYCIN + RT | 101587976 |
| 10467505 | 10042315 | 1.57 | 68.3 | Adjuvant (A) | null | 2018-08-11 | TRASTUZUMAB EMTANSINE | N | N | BORTEZOMIB + PANOBINOSTAT | 101066657 |
| 10467679 | 10042317 | 1.89 | 84 | Curative (C) | 2021-01-13 | 2021-01-19 | Cisplatin + Pemetrexed | N | null | CISPLATIN + CAPECITABINE + EPIRUBICIN | 100630447 |
| 10467889 | 10042321 | 1.65 | 0 | Curative (C) | null | 2018-11-19 | CVP | null | N | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 100507259 |
| 10467904 | 10042322 | 1.71 | 80 | 03 | 2019-06-14 | 2019-06-17 | CARBOPLATIN + GEMCITABINE | 02 | N | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 101058072 |
| 10468004 | 10042323 | 1.76 | 80.7 | 03 | null | 2021-11-14 | LENVATINIB | N | N | ABVD | 101096281 |
| 10468045 | 10042324 | null | null | Neo-adjuvant (N) | 2019-04-02 | 2019-04-10 | DACARBAZINE + DOXORUBICIN + VINBLASTINE | 2 | null | IPILIMUMAB | 100822004 |
| 10468198 | 10042325 | 1.83 | 82.4 | Palliative (P) | 2018-07-18 | 2018-07-26 | Cisplatin + Radiotherapy | 02 | N | DA | 100547929 |
| 10468274 | 10042329 | 1.48 | 78.1 | Palliative (P) | 2016-01-07 | 2016-01-15 | MPV (cycle 1-4) | 02 | N | FLUDARABINE + MITOXANTRONE | 100882473 |
| 10468334 | 10042332 | 1.6 | 63 | null | 2022-05-03 | 2022-05-17 | Letrozole + Palbociclib | 02 | null | TRASTUZUMAB | 101379951 |
| 10468465 | 10042333 | 1.59 | 67.05 | Palliative (P) | null | 2018-11-27 | Bortezomib + Cyclophos + Dex | null | N | GEMCITABINE + NAB-PACLITAXEL | 101175957 |
| 10468511 | 10042334 | 1.68 | 81.3 | Curative (C) | 2017-07-19 | 2017-07-26 | DABRAFENIB | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101838528 |
| 10468569 | 10042335 | 1.72 | 65.7 | null | 2016-06-27 | 2016-07-03 | ECF | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101725495 |
| 10468587 | 10042336 | 1.72 | 64.3 | Neo-adjuvant (N) | null | 2019-06-05 | Methotrexate 10mg/m2 po 7day | 02 | N | LENVATINIB | 101601986 |
| 10468761 | 10042337 | 1.69 | 60 | null | 2018-03-27 | 2018-04-09 | IDELALISIB | N | Y | CVP R + GEMCITABINE | 100421318 |
| 10468832 | 10042338 | 0 | 80.4 | null | 2018-06-27 | 2018-07-03 | AML 18 TRIAL | 02 | N | FLAIR TRIAL | 101693728 |
| 10468903 | 10042340 | 1.69 | 60.9 | Curative (C) | 2018-03-03 | 2018-03-21 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + METHOTREXATE + RITUXIMAB + VINCRISTINE | 100130966 |